ABPWW — Abpro Holdings, Inc.

—
OTC · Health Care · Biotechnology · CIK 1893219 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -1,175,000 -940,000 5,241,000 4,236,000 8,225,000
Mar 2026 0 — -933,000 -1,028,000 6,865,000 5,398,000 9,117,000
Dec 2025 0 — 2,504,000 5,636,000 1,063,000 67,000 9,345,000
Sep 2025 0 — -1,336,000 -1,657,000 1,703,000 328,000 17,298,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,588,000
Investing CF
$0
Financing CF
$8,769,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-120,963,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$3,374,000
Pretax Income TTM
$2,011,000
Interest Exp TTM
$1,363,000
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -4,051,000 -2,892,000 1,063,000 9,345,000 -8,831,000 -6,006,000
Dec 2024 183,000 -9,921,000 -7,232,000 4,661,000 19,607,000 -15,495,000 -9,030,000
Dec 2023 122,000 -11,746,000 -11,706,000 3,355,000 91,790,000 -88,984,000 -7,402,000
Dec 2022 2,029,000 -16,685,000 -17,215,000 11,852,000 87,586,000 -76,283,000 -8,952,000

TTM Snapshot

Revenues TTM
$70,000
NetIncome TTM
$2,011,000
OpCashFlow TTM
—
Assets (Latest)
$5,241,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $247.70B $457.93 —
GILD GILEAD SCIENCES, INC. $211.18B $170.26 —
MRNA Moderna, Inc. $82.56B $206.80 —
ARGX ARGENX SE $58.92B $947.52 —
BIIB BIOGEN INC. $37.07B $250.79 —

News headlines (Yahoo Finance, 1h cache)

Delisting of Securities from The Nasdaq Stock Market
2026-09-17 13:00 · Yahoo
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
2026-01-06 12:00 · Yahoo
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
2025-12-15 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.